News
Events
New Study published validating further Nevisense indication, Non-melanoma Skin Cancer
December 8, 2020New clinical study supports expansion of indications for Nevisense Study performed in Germany validates the use of Nevisense in non-melanoma skin cancer The study publication is an important milestone in the plan...SciBase announces changes to the Management team
November 4, 2020Linn Olsen, SciBase's head of production and supply chain, has been appointed as a member of the management team. "Our manufacturing of single use electrodes is of strategic importance to the Company an...Positive step for US reimbursement of Nevisense
November 2, 2020STOCKHOLM, SWEDEN, - November 2, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that they have been granted a Category III CPT®(CPT III) code from the American Medical Association (AMA) for their Nevisense melanoma detection test.
- Load more news...